MX9702357A - Spray-dried microparticles as therapeutic vehicles. - Google Patents

Spray-dried microparticles as therapeutic vehicles.

Info

Publication number
MX9702357A
MX9702357A MX9702357A MX9702357A MX9702357A MX 9702357 A MX9702357 A MX 9702357A MX 9702357 A MX9702357 A MX 9702357A MX 9702357 A MX9702357 A MX 9702357A MX 9702357 A MX9702357 A MX 9702357A
Authority
MX
Mexico
Prior art keywords
spray
dried microparticles
therapeutic
agent
therapeutic vehicles
Prior art date
Application number
MX9702357A
Other languages
Spanish (es)
Other versions
MXPA97002357A (en
Inventor
Andrew Derek Sutton
Richard Alan Johnson
Original Assignee
Andaris Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Andaris Ltd filed Critical Andaris Ltd
Publication of MXPA97002357A publication Critical patent/MXPA97002357A/en
Publication of MX9702357A publication Critical patent/MX9702357A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Physics & Mathematics (AREA)
  • Acoustics & Sound (AREA)
  • Radiology & Medical Imaging (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Microparticles of a water-soluble material, which are smooth and spherical, and at least 90 percent of which have a mass median particle size of 1 to 10 'mu'm, and which either carry a therapeutic or diagnostic agent or use such an agent as the water-soluble material, can successfully be used in dry powder inhalers to deliver the said agent.
MX9702357A 1994-09-29 1995-09-26 Spray-dried microparticles as therapeutic vehicles. MX9702357A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP94307126 1994-09-29
EP94307126.6 1994-09-29
PCT/GB1995/002279 WO1996009814A1 (en) 1994-09-29 1995-09-26 Spray-dried microparticles as therapeutic vehicles

Publications (2)

Publication Number Publication Date
MXPA97002357A MXPA97002357A (en) 1997-06-01
MX9702357A true MX9702357A (en) 1997-06-28

Family

ID=8217866

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9702357A MX9702357A (en) 1994-09-29 1995-09-26 Spray-dried microparticles as therapeutic vehicles.

Country Status (16)

Country Link
EP (1) EP0783298A1 (en)
JP (1) JPH10506406A (en)
KR (1) KR970705979A (en)
AU (1) AU701440B2 (en)
BR (1) BR9509171A (en)
CA (1) CA2199954A1 (en)
CZ (1) CZ92497A3 (en)
FI (1) FI971332A (en)
HU (1) HUT77373A (en)
MX (1) MX9702357A (en)
NO (1) NO971438L (en)
NZ (1) NZ292980A (en)
PL (1) PL319600A1 (en)
RU (1) RU2147226C1 (en)
WO (1) WO1996009814A1 (en)
ZA (1) ZA958239B (en)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6051256A (en) * 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
US5955108A (en) * 1994-12-16 1999-09-21 Quadrant Healthcare (Uk) Limited Cross-linked microparticles and their use as therapeutic vehicles
GB9606188D0 (en) * 1996-03-23 1996-05-29 Danbiosyst Uk Pollysaccharide microspheres for the pulmonary delivery of drugs
GB9606677D0 (en) * 1996-03-29 1996-06-05 Glaxo Wellcome Inc Process and device
GB9607035D0 (en) * 1996-04-03 1996-06-05 Andaris Ltd Spray-dried microparticles as therapeutic vehicles
GB9610341D0 (en) * 1996-05-17 1996-07-24 Andaris Ltd Formulation for inhalation
EP0914096B1 (en) * 1996-05-17 2003-08-13 Elan Drug Delivery Limited Microparticles and their use in wound therapy
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5855913A (en) * 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
USRE37053E1 (en) 1996-05-24 2001-02-13 Massachusetts Institute Of Technology Particles incorporating surfactants for pulmonary drug delivery
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
GB9615435D0 (en) * 1996-07-23 1996-09-04 Andaris Ltd Spray-dried product and its therapeutic use
JP2002515887A (en) * 1996-10-19 2002-05-28 クウォドラント、ヘルスケアー、（ユーケー）、リミテッド Use of hollow microcapsules in diagnosis and therapy
GB9621825D0 (en) * 1996-10-19 1996-12-11 Andaris Ltd Microparticles and their use as therapeutic vehicles
EP0952821A4 (en) * 1996-12-31 2006-07-26 Nektar Therapeutics Processes for spray drying aqueous suspensions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes
EP1498115A1 (en) * 1997-01-16 2005-01-19 Massachusetts Institute Of Technology Preparation of particles for inhalation
ATE287257T1 (en) * 1997-01-16 2005-02-15 Massachusetts Inst Technology PREPARATION OF PARTICLE-CONTAINING MEDICINAL PRODUCTS FOR INHALATION
SE9700133D0 (en) * 1997-01-20 1997-01-20 Astra Ab New formulation
DE69814428T2 (en) * 1997-09-29 2004-05-13 Nektar Therapeutics, San Carlos PREPARED, STABILIZED PREPARATIONS
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
SE9704186D0 (en) 1997-11-14 1997-11-14 Astra Ab New composition of matter
GB9727102D0 (en) * 1997-12-22 1998-02-25 Andaris Ltd Microparticles and their therapeutic use
AU2540299A (en) * 1998-02-20 1999-09-06 Quadrant Healthcare (Uk) Limited Products comprising fibrinogen for use in therapy
EP1273290A1 (en) * 1998-06-24 2003-01-08 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
JP2002518432A (en) * 1998-06-24 2002-06-25 アドバンスト インハレーション リサーチ，インコーポレイテッド Large porous particles released from an inhaler
WO2000062819A1 (en) * 1999-04-21 2000-10-26 1355540 Ontario Inc. Formulations for detecting asthma
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
EP1239844B1 (en) 1999-12-20 2005-06-08 Nicholas J. Kerkhof Process for producing nanometer particles by fluid bed spray-drying
US8771740B2 (en) * 1999-12-20 2014-07-08 Nicholas J. Kerkhof Process for producing nanoparticles by spray drying
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
WO2001093837A2 (en) * 2000-06-08 2001-12-13 Eli Lilly And Company Protein powder for pulmonary delivery
CA2432175C (en) 2000-12-21 2010-08-10 Jayne E. Hastedt Storage stable powder compositions of interleukin-4 receptor
GB0111420D0 (en) * 2001-05-10 2001-07-04 Biovector Solutions Ltd Soluble polymer systems for drug delivery
EP1992335A1 (en) 2001-11-01 2008-11-19 Nektar Therapeutics Spray drying methods and compositions thereof
US7368102B2 (en) 2001-12-19 2008-05-06 Nektar Therapeutics Pulmonary delivery of aminoglycosides
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
WO2004057959A2 (en) 2002-12-20 2004-07-15 Generipharm, Inc. Intracutaneous injection
MXPA05012821A (en) 2003-05-28 2006-02-13 Nektar Therapeutics Pharmaceutical formulation comprising a water-insoluble active agent.
SG135204A1 (en) 2003-07-18 2007-09-28 Baxter Int Methods for fabrication, uses and compositions of small spherical particles prepared by controlled phase separation
DE10339197A1 (en) * 2003-08-22 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Spray-dried amorphous powder with low residual moisture and good storage stability
US7727962B2 (en) 2004-05-10 2010-06-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder comprising new compositions of oligosaccharides and methods for their preparation
US7611709B2 (en) 2004-05-10 2009-11-03 Boehringer Ingelheim Pharma Gmbh And Co. Kg 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
US7723306B2 (en) 2004-05-10 2010-05-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation
CN103393601A (en) 2004-05-12 2013-11-20 巴克斯特国际公司 Microspheres comprising protein and showing injectability at high concentration of protein
EP2077821B1 (en) 2006-10-12 2019-08-14 The University Of Queensland Compositions and methods for modulating immune responses
EP2050437A1 (en) * 2007-10-15 2009-04-22 Laboratoires SMB Improved pharmaceutical dry powder compositions for inhalation.
UA90013C2 (en) * 2008-03-19 2010-03-25 Давид Анатолійович Нога Pharmaceutical composition containing insulin and process for the preparation thereof
US11524058B2 (en) 2008-09-29 2022-12-13 The Corporation Of Mercer University Oral dissolving films containing microencapsulated vaccines and methods of making same
US10463608B2 (en) 2008-09-29 2019-11-05 The Corporation Of Mercer University Microneedle-based transdermal delivery system and method of making same
US10004790B2 (en) 2008-09-29 2018-06-26 The Corporation Of Mercer University Nanospheres encapsulating bioactive material and method for formulation of nanospheres
US9149441B2 (en) 2008-09-29 2015-10-06 The Corporation Of Mercer University Nanospheres encapsulating bioactive material and method for formulation of nanospheres
US9827205B2 (en) 2008-12-12 2017-11-28 Mallinckrodt Pharma Ip Trading D.A.C. Dry powder fibrin sealant
EP2216054A1 (en) 2009-02-06 2010-08-11 ProFibrix BV Biodegradable extravascular support
GB0909136D0 (en) 2009-05-28 2009-07-01 Profibrix Bv Dry powder composition
GB0909131D0 (en) 2009-05-28 2009-07-01 Quadrant Drug Delivery Ltd Dry powder fibrin sealant
CA2761903C (en) * 2009-05-28 2018-04-10 Profibrix B.V. Dry powder fibrin sealant
WO2011005756A1 (en) 2009-07-06 2011-01-13 Puretech Ventures, Llc Delivery of agents targeted to microbiota niches
US8846105B2 (en) 2010-01-08 2014-09-30 Profibrix, B.V. Dry powder fibrin sealant
WO2012012460A1 (en) 2010-07-19 2012-01-26 Xeris Pharmaceuticals, Inc. Stable glucagon formulations for the treatment of hypoglycemia
EP2635596B8 (en) 2010-11-01 2020-03-11 University of Technology Sydney Immune-modulating agents and uses therefor
EP3225235B1 (en) 2011-03-10 2020-12-16 Xeris Pharmaceuticals, Inc. Stable peptide formulations for parenteral injection
EA028572B1 (en) 2011-03-10 2017-12-29 Ксерис Фармасьютикалс, Инк. Stable formulation for parenteral injection and method of making and using the same
RU2013155713A (en) 2011-07-06 2015-08-20 Профибрикс Бв COMPOSITIONS FOR TREATMENT OF THE RAS
AU2012332556B2 (en) 2011-10-31 2016-05-26 Xeris Pharmaceuticals, Inc. Formulations for the treatment of diabetes
KR20140147891A (en) 2012-04-13 2014-12-30 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Aggregate particles
IN2014DN10714A (en) 2012-06-26 2015-09-04 Ge Healthcare As
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
JP6328146B2 (en) 2013-02-01 2018-05-23 グリアロジクス・インコーポレイテッドＧｌｉａｌｏｇｉｘ， Ｉｎｃ． Compositions and methods for the treatment of neurodegeneration and other diseases
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
WO2014124096A1 (en) 2013-02-06 2014-08-14 Perosphere Inc. Stable glucagon formulations
JP6529012B2 (en) 2013-10-08 2019-06-12 エイアイ・セラピューティクス・インコーポレーテッド Rapamycin for the treatment of lymphangiyomyomatosis
CA2944075C (en) 2014-04-04 2022-06-28 Lam Therapeutics, Inc. An inhalable rapamycin formulation for treating age-related conditions
EP4198059A1 (en) 2014-05-27 2023-06-21 The University of Queensland Modulation of cellular stress
JP6982495B2 (en) 2014-08-06 2021-12-17 ゼリス ファーマシューティカルズ インコーポレイテッド Syringes, kits, and methods for intradermal and / or subcutaneous injection of paste
RU2732908C2 (en) 2014-10-07 2020-09-24 ЭйАй ТЕРАПЬЮТИКС, ИНК. Inhalation dosage form of rapamycin for treating pulmonary hypertension
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
WO2016196976A1 (en) 2015-06-04 2016-12-08 Xeris Pharmaceuticals, Inc. Glucagon delivery apparatuses and related methods
WO2016201248A1 (en) 2015-06-10 2016-12-15 Xeris Pharmaceuticals, Inc. Use of low dose glucagon
US11590205B2 (en) 2015-09-25 2023-02-28 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
WO2017062463A1 (en) 2015-10-05 2017-04-13 The Corporation Of Mercer University Nanospheres encapsulating bioactive material and method for formulation of nanospheres
US11628208B2 (en) 2015-10-05 2023-04-18 The Corporation Of Mercer University System and method for microneedle delivery of microencapsulated vaccine and bioactive proteins
US20180110760A1 (en) 2016-10-21 2018-04-26 Glialogix, Inc. Compositions and methods for the treatmentof neurodegenerative and other diseases
EP4378463A2 (en) 2017-06-02 2024-06-05 Xeris Pharmaceuticals, Inc. Precipitation resistant small molecule drug formulations
WO2021090214A2 (en) * 2019-11-04 2021-05-14 Alesco S.R.L. Sucrosomial® berberine, its compositions and their use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2177544T3 (en) * 1992-06-12 2002-12-16 Teijin Ltd ULTRAFININE POWDER TO INHALATE AND METHOD FOR PREPARATION.
DE69330672T2 (en) * 1992-06-12 2002-06-27 Teijin Ltd PHARMACEUTICAL PREPARATION FOR APPLICATION IN THE AIRWAY

Also Published As

Publication number Publication date
CZ92497A3 (en) 1997-08-13
NO971438D0 (en) 1997-03-26
BR9509171A (en) 1997-09-16
FI971332A0 (en) 1997-04-01
KR970705979A (en) 1997-11-03
NO971438L (en) 1997-03-26
AU701440B2 (en) 1999-01-28
NZ292980A (en) 1999-02-25
FI971332A (en) 1997-04-01
ZA958239B (en) 1996-09-30
PL319600A1 (en) 1997-08-18
JPH10506406A (en) 1998-06-23
CA2199954A1 (en) 1996-04-04
WO1996009814A1 (en) 1996-04-04
RU2147226C1 (en) 2000-04-10
AU3530295A (en) 1996-04-19
HUT77373A (en) 1998-03-30
EP0783298A1 (en) 1997-07-16

Similar Documents

Publication Publication Date Title
MX9702357A (en) Spray-dried microparticles as therapeutic vehicles.
EP0392426A3 (en) Emulsifier-free hand and body lotion
EP0951917A3 (en) Particle delivery of particularly a powdered therapeutical agent
PL347640A1 (en) Dry powder for inhalation
GB9606677D0 (en) Process and device
MX9709448A (en) Methods and system for processing dispersible fine powders.
EP2258342A3 (en) Improvements in and relating to carrier particles for use in dry powder inhalers
WO2003024396A3 (en) Dry powder medicament formulations
WO2003105780A3 (en) A dry powder oligonucleotide formulation, preparation and its uses
EP1213012A3 (en) Improvements in and relating to powders for use in dry powder inhalers
FR2727689B1 (en)
WO2001074310A3 (en) Leave-in hair cosmetic compositions for enhancing volume containing microspheres
CA2195065A1 (en) Inhalation composition
BG104253A (en) Perforated microparticles and method for their utilization
WO1996018388A3 (en) Cross-linked microparticles and their use as therapeutic vehicles
TW280780B (en)
NZ336592A (en) Formulation for inhalation having a poured bulk density of from 0.28 to 0.38 g/ml comprising finely divided budesonide and a carrier
CA2277890A1 (en) New formulation for inhalation having a poured bulk density of from 0.28 to 0.38 g/ml, comprising formoterol
AR007493A1 (en) SPRAY DRIED MICROPARTICLES AS THERAPEUTIC VEHICLES FOR USE IN GENETIC THERAPY
AU3012901A (en) Antiperspirant composition
EP0847773A3 (en) Electrotherapy device with electrostatic skin adhering pads and charging device
ES2096521A1 (en) Microspheres of biodegradable synthetic polymers in the manufacture of reactive equipment for the preparation of radiopharmaceuticals.
GB9810806D0 (en) Odour absorbing agent
DE59803568D1 (en) Hautpflegemittel enthaltend hydroxycarbonsäurealkylester (cosmacol) und polymethacrylat copolymer (polytrap)
TH50858A (en) Powder cosmetic compound containing silicone elastomer